title: Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants.
abstract: Bacterial L-asparaginases have been used as anti-cancer drugs for over 4 decades though presenting, along with their therapeutic efficacy, several side effects due to their bacterial origin and, seemingly, to their secondary glutaminase activity. Helicobacter pylori type II L-asparaginase possesses interesting features, among which a reduced catalytic efficiency for L-GLN, compared to the drugs presently used in therapy. In the present study, we describe some enzyme variants with catalytic and in vitro cytotoxic activities different from the wild type enzyme. Particularly, replacements on catalytic threonines (T16D and T95E) deplete the enzyme of both its catalytic activities, once more underlining the essential role of such residues. One serendipitous mutant, M121C/T169M, had a preserved efficiency vs L-asparagine but was completely unable to carry out L-glutamine hydrolysis. Interestingly, this variant did not exert any cytotoxic effect on HL-60 cells. The M121C and T169M single mutants had reduced catalytic activities (nearly 2.5- to 4-fold vs wild type enzyme, respectively). Mutant Q63E, endowed with a similar catalytic efficiency versus asparagine and halved glutaminase efficiency with respect to the wild type enzyme, was able to exert a cytotoxic effect comparable to, or higher than, the one of the wild type enzyme when similar asparaginase units were used. These findings may be relevant to determine the role of glutaminase activity of L-asparaginase in the anti-proliferative effect of the drug and to shed light on how to engineer the best asparaginase/glutaminase combination for an ever improved, patients-tailored therapy.
authors: Department of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, Italy; Department of Biology and Biotechnologies "Lazzaro Spallanzani", Laboratory of Protein Biochemistry, University of Pavia, Pavia, Italy.
authors: Maristella
authors: M
authors: Maggi
authors: Department of Biology and Biotechnologies "Lazzaro Spallanzani", Laboratory of Molecular Microbiology, University of Pavia, Pavia, Italy.
authors: Laurent R
authors: LR
authors: Chiarelli
authors: Department of Biology and Biotechnologies "Lazzaro Spallanzani", Laboratory of Protein Biochemistry, University of Pavia, Pavia, Italy.
authors: Giovanna
authors: G
authors: Valentini
authors: Department of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, Italy.
authors: Claudia
authors: C
authors: Scotti
mesh_terms: D000581:Amidohydrolases / Q000494:pharmacology; D001215:Asparaginase / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism; D020134:Catalytic Domain; D049109:Cell Proliferation / Q000187:drug effects; D005818:Genetic Engineering / Q000379:methods; D005972:Glutaminase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D018922:HL-60 Cells; D016480:Helicobacter pylori / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D009154:Mutation; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D013912:Threonine / Q000235:genetics / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D013912:Threonine; D000581:Amidohydrolases; D001215:Asparaginase; D005972:Glutaminase; C020654:glutamin-(asparagin-)ase